San Diego, CA, United States of America

Caty E DeJesus

This inventor holds 1 USPTO granted patent. Top assignee: Chiron Viagene, Inc.. Active years: 1997.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Caty E DeJesus: Innovator in Anti-Cancer Immunotherapeutics

Introduction

Caty E DeJesus is a prominent inventor based in San Diego, California. She has made significant contributions to the field of immunotherapy, particularly in the development of anti-cancer treatments. Her innovative approach focuses on utilizing vector constructs to target and destroy tumor cells effectively.

Latest Patents

Caty E DeJesus holds a patent for her invention titled "Anti-cancer immunotherapeutics." This patent outlines a method for destroying selected tumor cells by administering a vector construct that directs the expression of immunogenic, non-tumorigenic forms of altered cellular components associated with the tumor cells. The invention includes various vector constructs and recombinant viruses that carry these constructs, providing a promising avenue for cancer treatment.

Career Highlights

Throughout her career, Caty has been associated with Chiron Viagene, Inc., where she has worked on groundbreaking research in cancer immunotherapy. Her dedication to advancing medical science has positioned her as a key figure in her field.

Collaborations

Caty has collaborated with notable colleagues, including Jack R Barber and Mordechai Bodner. These partnerships have contributed to her success and the development of innovative solutions in cancer treatment.

Conclusion

Caty E DeJesus is a trailblazer in the realm of anti-cancer immunotherapeutics, with her patent showcasing her commitment to fighting cancer through innovative methods. Her work continues to inspire advancements in medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…